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ABSTRACT
Objective: Although fragility fractures of the distal radius are common, osteoporosis treatment requires exploration as attempts to improve 
postfracture investigations have been only partially successful. Bisphosphonates may help minimize the risk of secondary fractures but being a potent 
antiresorptive agent; it raises concerns about adverse effects on the healing process. This observational study examines the effect of bisphosphonate 
(alendronate) on healing of acute fractures of distal radius through 66 patients aged >45 years admitted to two tertiary care hospitals in Mangalore 
from May 2014 to September 2016.
Methods: The methodology consists of purposive sampling from two groups: Control having 33 patients not on alendronate therapy and cases 
comprising 33 who are on alendronate as part of prophylaxis for osteoporosis before fracture occurrence, with outpatient reviews at 2-week intervals 
starting from the 6th till fracture union seen. At each visit, plain radiographs of the involved wrist were taken to yield time to cortical bridging, with 
range of active movement of the affected wrist taken using a goniometer. Data were analyzed using Statistical Package for the Social Sciences software 
version 17.0 for t values, p values and correlations and results were presented in the form of graphs and tables.
Results: No significant differences were observed in the groups (as per p values) w.r.t. gender (0.804), age (0.835), time to healing (1.000), dorsiflexion 
(0.956), palmar flexion (0.670), ulnar deviation (0.441), radial deviation (1.000), supination (0.132), or pronation (0.302). Quick Disabilities of the 
Arm, Shoulder and Hand score did not differ by >95% between the groups over the analysis period.
Conclusion: It was observed that alendronate administration in distal radius fractures did not appear to delay fracture healing times radiologically 
or clinically.
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INTRODUCTION
Although fragility fractures of the distal radius are common mostly in 
women in their 60s or 70s [1], treatment for osteoporosis after such 
fractures requires in-depth exploration. These fractures are seen to 
occur at a younger age in patients in comparison with other major 
osteoporotic fractures [2] and are the most common fractures to occur 
in the postmenopausal period [3]. Treatments targeted at improving 
postfracture investigations of osteoporosis have only been partially 
successful [4].
Treatment using bisphosphonates following a fracture could help in 
minimizing the risk of a secondary fracture [5]. However, the possibilities 
of adverse effects of these drugs on the healing process of fractures due 
to them being antiresorptive agents must always be considered [6]. Tests 
have been performed on both animals as well as humans in different 
studies to understand the interaction between bisphosphonates and the 
fracture healing process. Animal studies have indicated that inhibition 
of the hard callus remodeling to mature lamella bone occurs as a 
consequence of bisphosphonates [7,8]. However, studies on humans, in 
the same manner, have not led to definitive results [9].
The objective of this study is to “examine the effect of bisphosphonate 
(alendronate) on the healing of acute fractures of the distal radius.” The 
study population consisted of 66 patients aged 45 years and above, who 
were admitted to the Government Wenlock Hospital and the Kasturba 
Medical College (KMC) Hospital in Attavar, Mangalore, from May 2014 
to September 2016.
The scope of the study extends to determining the level to which 
administration of alendronate on patients has changed the way that 
their fractures have healed with reference to those who were not on 
the alendronate therapy, by examining time of healing, and functional 
evaluation through Quick Disabilities of the Arm, Shoulder and Hand 
(QuickDASH) scores.
METHODS
A total of 66 patients aged 45 years and above with acute fragility 
fractures of the distal radius who presented themselves to the 
outpatient department of the Government Wenlock Hospital and 
KMC, Mangalore, from the period dating from May 2014 to September 
2016, were considered for this study. 38 patients were excluded from 
the study based on exclusion criteria and noncompliance with regular 
follow-up. Group allocation was carried out based on the patients visit 
to the hospital, with cases and controls alternating with each other. 
It was found that patients who did not take prophylaxis outweighed 
patients who did. Hence, once each case was selected, every other 
patient who satisfied as a control was discarded from the study until 
a patient who met the criteria for a case was enrolled. 127 patients 
who met the criteria for control were thereby discarded in the process. 
The study has been done in compliance with and on approval from the 
Institutional Ethics Committee, KMC, Mangalore.
Patients with associated fracture of the ulnar styloid were not excluded 
from the study. Patients with rheumatoid arthritis, chronic renal disease, 
dementia, open fractures, associated neurovascular complications 
identified at the time of enrollment, fractures with significant bone loss 
requiring bone graft or other graft materials, a concomitant fracture 
of metaphysis of distal ulna and comminuted fractures were excluded 
from this study.
© 2017 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
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Fractures were reduced manually under a hematoma block and 
visualized under image intensifier or using a radiograph. Those 
fractures which did not achieve reduction were taken up for surgical 
procedures and therefore excluded from the study. The fracture 
patterns were classified based on AO system.
Patients were made to complete the QuickDASH questionnaire to 
evaluate preinjury status. The QuickDASH is a validated 11-item 
questionnaire for the evaluation of upper extremity symptoms and 
function. Along with the QuickDASH questionnaire, the patients were 
required to fill a consent form for enrolment into the study along with 
details of age, sex, and hospital registration number. Patients were given 
follow-up dates 6 weeks after the first visit. When a patient arrived 
for the first follow-up visit at 6 weeks, plain anteroposterior (AP) and 
lateral view radiographs of the involved wrist were taken after removal 
of plaster cast after which cortical bridging was assessed at the fracture 
site. Fractures were deemed healed if at least 3 out of 4 cortices were 
found to be united. If union was not found in the first follow-up visit, 
they were asked to be available for review at 2-week intervals till union 
was noticed. At each visit along with plain radiographs, range of active 
movements (flexion, extension, supination, pronation, radial, and ulnar 
deviation) were measured with the assistance of a goniometer.
The following parameters were measured for each examined patient.
i. Time of healing (weeks): Time taken from the day of fracture 
reduction to the establishment of cortical bridging across the fracture 
fragments assessed from AP and lateral radiographs (union of 3 out 
of 4 cortices)
ii. QuickDASH score: Questionnaire which helps to determine preinjury 
status (detailed in the previous section)
iii.	 Dorsi	flexion:	Backward	flexion	of	the	hand	[10]
iv.	 Palmar	flexion:	Bending	the	hand	toward	the	palmar	surface	[10]
v. Ulnar deviation: Movement of the hand toward the ulnar side of the 
forearm [10]
vi. Radial deviation: Movement of the hand toward the radial side of the 
forearm [10]
vii. Supination: Turning the palm forward (anteriorly) or upward which 
is performed by lateral rotation of the forearm [10]
viii. Pronation: Turning the palm backward (posteriorly) which is 
performed by medial rotation of the forearm [10].
RESULTS
The primary outcome was the process of healing assessed radiologically 
by the observer. Other parameters were the range of movements of the 
wrist joint and the functional restriction as assessed by QuickDASH.
The following statistics were used for each of the above parameters to 
understand the statistical significance of each of them: Mean, standard 
deviation, t- and p-values as well as the Pearson’s correlation coefficient. 
From Table 1, it can be inferred that all parameters are seen to have a 
statistical significance which is <95% when looking at the cases and 
controls groups which are below the required range as per this study.
These results show that there is not a significant difference between 
patients who were being administered alendronate, to those who were 
not on the treatment, as demonstrated by their high p>0.05.
Graphs 1 and 2 shows the arithmetic mean of both the groups as well as 
for the total set for QuickDASH score as well as for the time of healing 
(weeks).
When looking at the correlations between parameters, the following 
results were seen as shown in Tables 2 and 3, which have been obtained 
from the software.
On close examination of the correlation values presented above, it 
can be seen that QuickDASH score correlates negatively with all other 
parameters in both cases and controls groupings. Time of healing 
correlates positively with all wrist movements and negatively with 
QuickDASH score in cases group, whereas in controls, it varies with each 
parameter. Correlations with significance >99% have been highlighted 
with ** and those with >95% significance with * as shown in Tables 1-3.
DISCUSSION
The study that was done in this paper aimed at examining the effect of 
alendronate on the healing of acute distal radius fractures in 66 patients 
aged higher than 45. It was concluded from this observational study that 
the administration of alendronate did not cause any adverse effects, as 
noted from radiological and clinical findings. There were found to be no 
significant differences in time of healing, QuickDASH score or any of the 
active wrist movements between patients who had been administered 
alendronate in comparison with those who were not on it when looking 
at statistical significances.
Bisphosphonates are effective therapeutic agents for an array of 
diseases related to the bone as they are good inhibitors of bone 
Table 1: Statistical derivations for cases, controls, and total 
groupings
Parameter Group N Mean±SD t‑value p value
Gender Cases 33 - 0.062 0.804
Controls 33
Total 66











Cases 33 7.27±1.790 0.000 1.000 NS
Controls 33 7.27±1.989
Total 66 7.27±1.877















Cases 33 12.27±5.741 0.000 1.000 NS
Controls 33 12.27±5.168
Total 66 12.27±5.419
Supination Cases 33 58.64±12.328 1.525 0.132 NS
Controls 33 54.09±11.888
Total 66 56.36±12.233
Pronation Cases 33 45.61±12.976 1.040 0.302 NS
Controls 33 42.47±13.056
Total 66 43.94±13.024
DASH: Disabilities of the Arm, Shoulder and Hand
Graph 1: Mean of groups and total for Quick Disabilities of the 
Arm, Shoulder and Hand score
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resorption [7]. Due to their effectiveness in reducing the incidence of 
fragility structures, they are highly favored as therapeutic agents for 
osteoporosis [7]. They are categorized into nitrogen-containing and 
non-nitrogen-containing bisphosphonates based on their mechanism 
of action. Nitrogen-containing bisphosphonates have the property 
of persisting for a considerable amount of time on the surface of the 
bone. This has, in turn, resulted in an increased use of these agents in 
clinical practice through dosing intermittently [7]. Alendronate is a 
bisphosphonate which contains nitrogen which is administered orally 
and the above-stated reasons have led to it being given at a daily and 
weekly dosage of almost 7 times that of the standard daily dose [7]. 
It is estimated to have 10 years as its skeletal half-life, and thus, it is 
crucial to dissect the possible consequences of intake of this drug 
because of its intrinsic ability to suppress osteoclast function which 
affects the process of fracture repair [11]. This could result in patients 
not achieving full recovery of this function for quite a period. However, 
due to it being a low-cost bisphosphonate with a wide spectrum of 
fracture efficacy, it is considered in most of the cases as the first line of 
treatment [12].
Tripathy et al. [13] in their study determine the clinical profile and 
prescription pattern of drugs in the treatment of osteoporosis in a tertiary 
care center in Karnataka noted in their findings that alendronate was 
the most commonly prescribed bisphosphonate (55.56%), prescribed 
as once weekly or once daily dose. Alendronate acts as a potent 
antiresorptive agent and inhibits farnesyl pyrophosphate synthase 
in osteoclasts, which need prenylated proteins for their function and 
survival [9]. As described in the paper by Uchiyama et al. [9] in 2013, the 
process of fracture healing is in the following order, though there exists 
some overlap between the stages: Inflammation, soft callus formation, 
hard callus formation, and hard callus remodeling. In the hard callus 
remodeling stage, osteoclasts are very much active. Alendronate is not 
seen to affect directly osteoblasts or other cells which participate in any 
of the first three stages mentioned above. Therefore, it can be inferred 
that callus formation radiologically, may not be affected by alendronate 
in a substantial manner; however, delays in remodeling of the hard 
callus could occur, as are also indicated in various animal studies. The 
process of bone remodeling goes hand in hand with other processes 
such as cartilage mineralization, vascular invasion as well as formation 
of the woven bone. Furthermore, osteoclasts are seen to be active from 
the beginning stages of fracture healing, removing necrotic bone from 
the fracture site. Hence, there always exists a possibility of delay in 
fracture healing occurring as a result of osteoclast dysfunction when 
administration of alendronate is started immediately.
Uchiyama et al., in 2013, [9] concluded from their study that 
administration of alendronate, early on after an operatively treated distal 
radius fracture did not seem to delay the healing of the fracture either 
radiologically or clinically, from their analysis of 80 patients overall with 






















Pearson correlation −0.095 −0.895** −0.845** −0.798** −0.773** −0.847** −0.877**
p 0.598 0.000 0.000 0.000 0.000 0.000 0.000
N 33 33 33 33 33 33 33
Time of healing (weeks)
Pearson correlation 0.118 0.000 0.123 0.379* 0.109 0.154
p 0.513 1.000 0.497 0.030 0.544 0.392
N 33 33 33 33 33 33
Dorsi flexion (0-70)
Pearson correlation ** 0.907** 0.754** 0.692** 0.836** 0.837**
p 0.000 0.000 0.000 0.000 0.000
N 33 33 33 33 33
Palmar flexion (0-80)
Pearson correlation ** ** 0.637** 0.594** 0.773** 0.744**
p 0.000 0.00 0.000 0.000
N 33 33 33 33
Ulnar deviation (0-35)
Pearson correlation ** ** ** 0.776** 0.760** 0.812**
p 0.000 0.000 0.000
N 33 33 33
Radial deviation (0-25)








Pearson correlation ** ** ** ** ** **
**Correlation is significant at the 0.01 level (two-tailed test). *Correlation is significant at the 0.05 level (two-tailed test). QuickDASH: Quick Disabilities of the Arm, 
Shoulder and Hand
Graph 2: Mean of groups and total for time of healing (weeks)
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40 being administered alendronate and 40, not being administered 
the drug. A double-blind study, in 2000, conducted by Van Der Poest 
Clement et al. [14] to examine how bone loss after a fracture in women 
having Colles’ fracture and postmenopausal osteoporosis is affected by 
alendronate; a 10 mg dosage of the drug or placebo was administered 
to 37 women who were diagnosed with distal forearm fracture and low 
bone mineral density (BMD) of the lumbar spine. Heightened levels of 
resorption combined with decreased formation resulted in bone loss 
after a fracture occurrence and in the immobilization period. Hike in 
the BMD of the hip and lumbar spine, as well as decrease in nonspine 
fracture incidence in postmenopausal women with osteoporosis, was 
seen to occur as a result of alendronate. A study conducted by Rozental 
et al. [15], in 2009, looked into a comparison of healing rates of distal 
radius fractures in patients who were on bisphosphonate therapy at the 
injury time with those who were not on it. A total of 196 patients were 
considered out of which the patients who were on the therapy were 43 
and those who were not, made up the control group with 153 patients. 
The factors which affected time to radiographic union were assessed 
using regression analysis and it was discovered that the average time 
to union was a bit lengthier in patients who were on bisphosphonate 
as opposed to those who were not it, with a ratio of 55 to 49 days. 
Thus, an increased time of healing was noted with bisphosphonate 
use, but that was deemed not satisfactory enough to demonstrate 
a clinical significance. Gong et al. [16] conducted a study in 2012 to 
determine the effect of early administration of bisphosphonate on the 
healing of osteoporotic distal radius fractures. This study focused on a 
randomized clinical trial to determine how safe it is for a patient who 
has an acute distal radius fracture to be administered bisphosphonates. 
It was inferred that osteoporotic medication after stable fracture 
fixation can be started early on in patients who faced a possible risk 
of future fracture. In their study to evaluate the effectiveness of certain 
bisphosphonates for the treatment of osteoporosis in postmenopausal 
women over the age of 50 in Tirana, Miraçi et al. [17] considered both 
alendronate as well as ibandronate.
Although the beneficial reasons for bisphosphonates may be justified from 
the improvements seen in patients, it is necessary to put in a word about 
the possible consequences of their usage. Bisphosphonates suppress the 
process of bone resorption by inhibiting osteoclast formation, which 
could in turn cause changes in remodeling, bone mineral content as 
well as affect the tensile strength of the healing bone [18]. In addition, a 
preferential deposition of oral and intravenous bisphosphonates at the 
site of an acute fracture has been noticed in many cases, and this could 
significantly affect clinical healing of these fractures [18]. Case studies 
performed by Odvina et al. [6], Goh et al. [19], and Kwek et al. [20] which 
looked into sets of atypical nonspine fractures of patients who have been 
on bisphosphonate therapy for a long period of time raised concerns about 
its usage. It was observed that fracture healing was delayed or absent for 
3 months up to 2 years for a significant number of these patients while 
they were on therapy. Atypical femoral fractures and osteonecrosis of the 
jaw are some of the consequences of the use of bisphosphonates on a 
long duration basis, and thus, the exact duration of administration has 
been a topic of dispute in the field of orthopedics [12]. It was seen that 
inhibition of the hard callus remodeling to mature lamella bone occurs as 
a result of bisphosphonate use in several animal studies which have been 
conducted [7,8]. While the risk of using bisphosphonates has been found 
to be statistically significant in many of these studies, it is a worthy point 
that the clinical significance is still unclear. Bisphosphonates are seen to 
be highly beneficial in decreasing fracture risk and it is a fact that the 
anguish and fatality associated with a new fracture occurrence is higher 
than that of nonunions which have been seen [15]. Hence, a proper 
evaluation of when to start the treatment following a fracture requires 
in-depth analysis as a delayed start must not result in initiation issues 
with these agents.
There are several limitations to this study which include the following 
points: Difficulty in finding out whether the patient has shown 
compliance in administration of the drug, limited number of subjects 
resulting in data compilation which may not be exactly accurate in a 























Pearson correlation −0.031 −0.735** −0.645** −0.586** −0.733** −0.715** −0.726**
p 0.864 0.000 0.000 0.000 0.000 0.000 0.000
N 33 33 33 33 33 33 33
Time of healing (weeks)
Pearson correlation 0.021 −0.014 0.137 0.014 −0.135 −0.151
p 0.906 0.940 0.446 0.939 0.455 0.402
N 33 33 33 33 33 33
Dorsi flexion (0-70)
Pearson correlation ** 0.872** 0.579** 0.598** 0.744** 0.832**
p 0.000 0.000 0.000 0.000 0.000
N 33 33 33 33 33
Palmar flexion (0-80)
Pearson correlation ** ** 0.573** 0.612** 0.827** 0.861**
p 0.000 0.00 0.000 0.000
N 33 33 33 33
Ulnar deviation (0-35)
Pearson correlation ** ** ** 0.734** 0.593** 0.630**
p 0.000 0.000 0.000
N 33 33 33
Radial deviation (0-25)








Pearson correlation ** ** ** ** ** **
**Correlation is significant at the 0.01 level (two-tailed test). QuickDASH: Quick Disabilities of the Arm, Shoulder and Hand
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real situation and inter observer variability in assessment of fracture 
healing.
CONCLUSION
It was observed that alendronate administration in distal radius 
fractures did not seem to delay fracture healing times either 
radiologically or clinically.
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